First-in-human results prompt a biomarker-defined approach for CID-078.
ApexOnco Front Page
Recent articles
AstraZeneca will soon start a phase 3 trial of a subcutaneous version of its anti-CD19 T-cell engager.
The “next-gen” PF-07985045 is gone, but the group has another pan-KRAS shot.
Furvent, in first-line EGFR exon 20 insertion lung cancer, reads out imminently.
Silevertinib trial will evaluate patients with unmethylated MGMT and EGFRvIII mutations.
Majestec-9, in post-Darzalex multiple myeloma, is the latest success.
JNJ-95566692 enters phase 1, with Qilu neck and neck.
But the company still has a lot to prove with ERAS-0015.
